AR and prostate carcinoma: Pharmacologic inhibition of PDE4D also suppresses prostate cancer growth by blocking sonic hedgehog, androgen receptor and MAPK pathways, and reverse tamoxifen resistance in estrogen receptor-positive breast cancer [378, 379].